Company Filing History:
Years Active: 2015-2016
Title: Sylvain Meloche: Innovator in Protein Degradation and SUMOylation
Introduction
Sylvain Meloche is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of biochemistry, particularly in the areas of protein degradation and SUMOylation. With a total of two patents to his name, Meloche's work has the potential to impact cancer treatment and protein analysis.
Latest Patents
Meloche's latest patents include an assay for inhibitors of CIP/KIP protein degradation. This innovative assay is designed for high throughput screening (HTS) and is capable of identifying small-molecule inhibitors that prevent the degradation of the Cdk inhibitor p21. The assay utilizes a fusion protein that combines a p2 polypeptide with a reporter protein linked to the C-terminal of the p21 polypeptide. This fusion protein has a half-life comparable to that of the p21 polypeptide, making it a valuable tool in cancer research. Another significant patent involves mutated SUMO isoforms, which includes nucleic acids encoding these isoforms, polypeptides, vectors, and methods for identifying and quantifying protein SUMOylation in mammalian cells. This dual affinity method enhances the detection of mutated SUMOylated protein substrate fragments.
Career Highlights
Sylvain Meloche is affiliated with the Université de Montréal, where he conducts his research and development. His work has garnered attention in the scientific community, particularly for its implications in cancer treatment and protein research.
Collaborations
Meloche collaborates with esteemed colleagues such as Anne Marinier and Benoit Pelletier, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Sylvain Meloche's contributions to the fields of protein degradation and SUMOylation highlight his role as an influential inventor. His patents not only advance scientific understanding but also hold promise for future therapeutic applications.